AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
Article content
AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (AI)-designed GLP-1 receptor agonist (GLP-1RA) peptide sequences achieve comparable or superior receptor activation to Semaglutide, a benchmark GLP-1 therapy and one of the most commercially successful drugs in the world. The in vitro analysis was conducted by an independent third party, further strengthening the objectivity and reliability of the findings.
Article content
The results validate the power of IPA's LENSai™ platform and its proprietary HYFT™ technology, which enables first-principles-based in silico peptide discovery and optimization. Five rationally engineered peptide sequences—AI-optimized for improved stability and peptidase resistance—were tested against benchmark GLP-1 analogs in receptor activation assays. Two lead candidates outperformed or matched Semaglutide under controlled assay conditions.
Article content
Crucially, the sequences were not discovered by chance. They were designed using HYFT-derived intrinsic biological patterns—mathematical representations of functional relationships in biology—making this approach highly reproducible and generalizable to other drug targets.
Article content
With GLP-1 therapies representing one of the fastest-growing segments in the global pharmaceutical market, these results demonstrate that AI can now generate not only predictive but functionally validated peptide drugs, paving the way for rapid expansion into adjacent therapeutic areas using the same HYFT-driven approach.
Article content
'This is not a one-off success,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'We've demonstrated a scalable, first-principles mechanism to design potent, stable, and biologically active peptide therapeutics. HYFT-guided design unlocks repeatable workflows for other validated targets—whether in cardiometabolic disease, oncology, or infectious disease. It represents a foundational shift in how therapeutics are discovered. The same LENSai-driven approach has already transformed our vaccine and antibody discovery programs, and we are now applying that rinse-and-repeat methodology to metabolic diseases—starting with GLP-1.'
Article content
IPA is now considering two complementary preclinical paths for its lead GLP-1 candidates:
Article content
Injectable delivery studies, including pharmacokinetic profiling and efficacy validation in animal models.
Non-invasive delivery strategies, including formulation work for transdermal patches and exploratory evaluation of nucleic acid-based delivery, designed to enhance durability, patient compliance, and ease of administration.
Article content
The sequences were also engineered for compatibility with next-generation expression systems, including nucleic acid-based vectors, which support scalable expression in both traditional and emerging human-relevant models, aligning with evolving regulatory interest in more predictive, flexible, and efficient therapeutic development approaches.
Article content
The significance of this breakthrough extends far beyond GLP-1. The same AI framework and HYFT-driven approach that generated these potent peptide drugs can now be applied to other high-value therapeutic targets—quickly, efficiently, and with built-in biological relevance.
Article content
This announcement follows IPA's recent success with AI-designed dengue virus vaccine candidates, reinforcing the broad applicability of its technology across both infectious and non-infectious diseases.
Article content
About ImmunoPrecise Antibodies Ltd.
Article content
ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT™ technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models.
Article content
Forward-Looking Statements
Article content
This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, those related to the anticipated benefits, scalability, translatability, adoption, and broader application of the LENSai™ and HYFT® platforms; the advancement and regulatory acceptance of AI-native drug discovery methods; the continued development and potential preclinical or clinical progression of IPA's AI-designed GLP-1 peptide program; the feasibility of next-generation delivery strategies; and the Company's ongoing ability to maintain scientific, regulatory, and commercial momentum in this and related therapeutic areas.
Article content
Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. Such factors include, but are not limited to, scientific or technological developments, changes in regulatory requirements or acceptance of AI-designed therapeutics, competitive or market dynamics, intellectual property protection and enforcement, risks related to preclinical or clinical validation, integration or operational risks, and changes in economic or business conditions.
Article content
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar). Should any of these risks materialize, actual results could vary significantly from those currently anticipated.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
AMD turns to AI startups to inform chip, software design
Advanced Micro Devices (AMD) chips are displayed at the Micro Center computer store in Santa Clara, Calif., Wednesday, Jan. 19, 2011. (AP Photo/Paul Sakuma) SAN JOSE -- Advanced Micro Devices has forged close ties to a batch of artificial intelligence startups as part of the company's effort to bolster its software and forge superior chip designs. As AI companies seek alternatives to Nvidia's chips, AMD has begun to expand its plans to build a viable competing line of hardware, acquiring companies such as server maker ZT Systems in its quest to achieve that goal. But to build a successful line of chips also requires a powerful set of software to efficiently run the programs built by AI developers. AMD has acquired several small software companies in recent weeks in a bid to boost its talent, and it has been working to beef up its set of software, broadly known as ROCm. 'This will be a very thoughtful, deliberate, multi-generational journey for us,' said Vamsi Boppana, senior vice president of AI at AMD. AMD has committed to improve its ROCm and other software, which is a boon to customers such as AI enterprise startup Cohere, as it results in speedy changes and the addition of new features. Cohere is focused on building AI models that are tailored for large businesses versus the foundational AI models that companies like OpenAI and others target. AMD has made important strides in improving its software, Cohere CEO Aidan Gomez said in an interview with Reuters. Changing Cohere's software to run on AMD chips was a process that previously took weeks and now happens in only 'days,' Gomez said. Gomez declined to disclose exactly how much of Cohere's software relies on AMD chips but called it a 'meaningful segment of our compute base' around the world. OpenAI influence OpenAI has had significant influence on the design of the forthcoming MI450 series of AI chips, said Forrest Norrod, an executive vice president at AMD. AMD's MI400 series of chips will be the basis for a new server called 'Helios' that the company plans to release next year. Nvidia too has engineered whole servers in part because AI computations require hundreds or thousands of chips strung together. OpenAI's Sam Altman appeared on stage at AMD's Thursday event in San Jose, and discussed the partnership between the two companies in broad terms. Norrod said that OpenAI's requests had a big influence on how AMD designed the MI450 series memory architecture and how the hardware can scale up to thousands of chips necessary to build and run AI applications. The ChatGPT creator also influenced what kinds of mathematical operations the chips are optimized for. '(OpenAI) has given us a lot of feedback that, I think, heavily informed our design,' Norrod said. Reporting by Max A. Cherney in San JoseEditing by Shri Navaratnam, Reuters
Globe and Mail
an hour ago
- Globe and Mail
Want $400 in Passive Income? Invest $10,000 in These Dow Jones Stocks.
Building a large portfolio of dividend-paying companies can pay off handsomely in retirement. A 4% average yield on a small investment may not earn much today, but as you keep saving and investing in top dividend stocks, you could build a portfolio that pays $20,000 in annual income on $500,000 over time. The Dow Jones Industrial Average (DJINDICES: ^DJI) is a great place to look for rock-solid companies that pay high yields. Here are two Dow Jones stocks to buy today to start building your future passive income stream. 1. Home Depot Despite a weak housing market, Home Depot (NYSE: HD) stock has held up well over the past year. This speaks to its massive scale and leading position in the home improvement market. Higher interest rates continue to weigh on demand for home projects. Home Depot reported a total sales increase of 9% year over year in the first quarter, but it notched a slight decline in comparable-store sales. Regardless of how the economy performs in the near term, Home Depot offers attractive upside for long-term shareholders. It serves a large $1 trillion addressable market, and Home Depot has only captured about 17% of that opportunity. The company is particularly focused on going after business from professional contractors, which represents a $525 billion opportunity. Home Depot is also investing to diversify its supply chain from the impact of tariffs. It expects that no single country outside of the U.S. will represent more than 10% of its sourcing in the next 12 months. Once the home improvement market recovers, Home Depot can deliver double-digit annual earnings growth around 10%, which is consistent with its previous 10-year history. Home Depot paid 61% of its earnings in dividends last year, providing plenty of room to sustain the dividend despite the weak sales environment. The company has paid a dividend for 38 consecutive years, which covers quite a few bull-bear market cycles. It recently increased its quarterly dividend by 2% to $2.30, bringing its forward annual yield to 2.52%. An investor can expect to earn $126 in income over the next year from a $5,000 investment. 2. Verizon Communications Investors have been attracted to Verizon Communications ' (NYSE: VZ) high yield of more than 6%. The yield has gotten higher as the stock slid in recent years over increasing competition in the consumer wireless market, higher interest rates, and the company's high debt burden. However, the stock bounced back in 2025, as Verizon continues to reduce its debt and generate robust cash flows to fund its dividend. VZ data by YCharts As Verizon lays the groundwork for stronger performance in its wireless and broadband businesses, management is guiding for full-year free cash flow between $17.5 billion and $18.5 billion. This is more than enough to cover the dividend, which represented just 56% of its free cash flow over the last year. Leading telecom companies are attractive for dividend investors because of the recurring revenue from customers paying their monthly bills for phone and internet coverage. Verizon ended 2024 with more than 115 million consumer wireless retail connections and 10 million in broadband. This large base of customers helps the business generate consistent free cash flow to fund dividend payments. AT&T has experienced momentum recently in its wireless business, which has put pressure on Verizon. It's a very competitive industry, but Verizon's large annual revenue and free cash flow provide plenty of resources to invest in technology and features to protect its competitive position. On that note, Verizon reported an increase in average revenue per account last quarter. This reflects healthy demand for add-on services in myPlan, where customers can sign up for entertainment, insurance, and other perks. Verizon also just completed its acquisition of Frontier Communications for $20 billion, which will allow it to better compete with AT&T and T-Mobile in the broadband market. This comes after Verizon already reported gains in broadband market share in the first quarter. With Verizon continuing to reduce its debt burden, sentiment on the stock could improve and lift the shares higher. Investors can count on Verizon 's robust free cash flow to fund more dividend payments over the long term. It currently pays a quarterly dividend of $0.6775, bringing its forward yield to 6.2%. A $5,000 investment would earn $310 in income over the next 12 months. Should you invest $1,000 in Home Depot right now? Before you buy stock in Home Depot, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Home Depot wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $875,479!* Now, it's worth noting Stock Advisor 's total average return is998% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
an hour ago
- Globe and Mail
Where Will Confluent Stock Be in 3 Years?
It has been just under four years since Confluent (NASDAQ: CFLT) made its stock market debut in June 2021. A look at its stock price chart will show that investors in the data streaming specialist have endured a difficult time since November of that same year. Confluent stock was in fine form in 2021 following its initial public offering. However, like many other young tech stocks in late 2021, the stock price began a downhill run late in the year. Some of these stocks eventually recovered. In Confluent's case, the stock lost 46% of its value since its initial public offering (IPO) and 74% when compared to its all-time high. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Let's check why that has been the case and see if this cloud computing stock has the ability to regain its mojo and jump higher over the next three years. Confluent's expensive valuation has been the stock's undoing Confluent was trading at a whopping 37 times sales in 2021, which means that it needed to maintain high growth rates to justify its rich valuation. However, its sales growth rates have been dropping over the years, as we can see from the table below. Data source: Confluent quarterly reports. The reduction in Confluent's top-line growth is a big reason why the stock has fallen out of investors' favor. As a result, it is now trading at just under 8 times sales, which is lower than its five-year average price-to-sales ratio of 12. Another thing worth noting is that Confluent's sales multiple is now in line with the U.S. technology sector's average sales multiple. Buying Confluent at its current valuation could turn out to be a smart long-term move, as the company is now sitting on an added catalyst in the form of artificial intelligence (AI). Confluent's cloud-based data streaming platform is used by customers to bring data out of silos and connect it in real time to make decisions quickly. The company's platform finds applications in multiple areas such as inventory management, fraud detection, and customer service. It's now being applied in generative AI and agentic AI applications as well, as Confluent's platform allows customers to use relevant data in real time for training large language models (LLMs) and AI agents. As a result, Confluent is now winning a bigger share of customers' wallets, along with bringing new customers into its fold, which should set the company up for robust long-term growth. A massive addressable market points toward better times for the company Confluent now sees its addressable market exceeding $100 billion this year. That's double its estimated addressable market four years ago. Even better, the accelerated growth in its customer base suggests that it is well on track to capitalize on this massive opportunity. Confluent's overall customer base jumped by 20% year over year in the first quarter of 2025. That was a major improvement over the 9% year-over-year increase in its customer base in the year-ago period. Importantly, Confluent is gaining more business from its existing customers. This can be judged from the company's dollar-based net retention rate of 117%, a metric that compares its annual recurring revenue (ARR) from customers at the end of a quarter to the ARR from the same customer cohort in the year-ago period. So, an ARR of more than 100% suggests that existing customers are spending more money with Confluent. The higher spending by Confluent's older customers is also driving a solid bump in its margins. The company's non- GAAP operating margin increased by six percentage points year over year in Q1. This explains why the company's non-GAAP earnings increased by 60% from the year-ago period to $0.08 per share. The company has guided for $0.36 per share in earnings for 2025, which points toward a 24% increase from last year. However, don't be surprised to see Confluent doing better than that following the healthy increase in Q1, especially considering the pace at which it is adding new customers and encouraging existing ones to spend more money. Not surprisingly, analysts are forecasting an acceleration in Confluent's bottom-line growth over the next couple of years. Data by YCharts. The stronger growth in Confluent's earnings in 2026 and 2027 points toward better times for the stock over the next three years, as the market could reward this impressive bottom-line jump with healthy gains. As such, buying Confluent right now makes sense from a long-term point of view. The correction in the company's stock price since its IPO has made it a better buy, considering its lucrative end-market opportunity and bright prospects. Should you invest $1,000 in Confluent right now? Before you buy stock in Confluent, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Confluent wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $875,479!* Now, it's worth noting Stock Advisor 's total average return is998% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
